PetMed Express, Inc. (NASDAQ:PETS)‘s stock had its “underperform” rating restated by equities research analysts at Credit Suisse Group in a report released on Monday.

PETS has been the subject of a number of other research reports. ValuEngine upgraded PetMed Express from a “hold” rating to a “buy” rating in a research report on Friday, September 1st. BidaskClub cut PetMed Express from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, August 22nd. Craig Hallum cut PetMed Express from a “buy” rating to a “hold” rating in a research report on Tuesday, July 11th. Sidoti upgraded PetMed Express from a “neutral” rating to a “buy” rating and set a $47.00 price objective on the stock in a research report on Thursday, August 24th. Finally, Zacks Investment Research lowered PetMed Express from a “strong-buy” rating to a “hold” rating in a research note on Monday, September 25th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and four have assigned a buy rating to the stock. PetMed Express presently has an average rating of “Hold” and an average target price of $44.75.

PetMed Express (NASDAQ PETS) traded up 1.51% during mid-day trading on Monday, hitting $33.65. 109,328 shares of the stock traded hands. The company has a market cap of $682.83 million, a price-to-earnings ratio of 25.88 and a beta of 1.03. PetMed Express has a 12-month low of $18.90 and a 12-month high of $50.90. The firm’s 50-day moving average is $40.97 and its 200-day moving average is $33.60.

PetMed Express (NASDAQ:PETS) last released its earnings results on Monday, July 24th. The company reported $0.45 earnings per share for the quarter, topping analysts’ consensus estimates of $0.38 by $0.07. PetMed Express had a return on equity of 28.67% and a net margin of 10.34%. The business had revenue of $79.66 million for the quarter, compared to the consensus estimate of $77.32 million. During the same period last year, the business earned $0.32 earnings per share. The firm’s revenue for the quarter was up 9.9% compared to the same quarter last year. Equities research analysts expect that PetMed Express will post $1.44 EPS for the current year.

TRADEMARK VIOLATION WARNING: “PetMed Express’ (PETS) “Underperform” Rating Reaffirmed at Credit Suisse Group” was published by Watch List News and is the property of of Watch List News. If you are reading this piece on another website, it was illegally stolen and republished in violation of United States & international copyright & trademark legislation. The legal version of this piece can be accessed at https://www.watchlistnews.com/petmed-express-pets-underperform-rating-reaffirmed-at-credit-suisse-group/1603208.html.

In other PetMed Express news, Director Robert C. Schweitzer sold 2,500 shares of PetMed Express stock in a transaction that occurred on Tuesday, August 1st. The stock was sold at an average price of $49.18, for a total transaction of $122,950.00. Following the sale, the director now directly owns 88,834 shares of the company’s stock, valued at $4,368,856.12. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Bruce S. Rosenbloom sold 6,833 shares of PetMed Express stock in a transaction that occurred on Thursday, July 27th. The shares were sold at an average price of $50.18, for a total value of $342,879.94. Following the sale, the chief financial officer now directly owns 18,534 shares in the company, valued at $930,036.12. The disclosure for this sale can be found here. Insiders sold 19,333 shares of company stock valued at $949,730 in the last three months. Company insiders own 4.00% of the company’s stock.

Several institutional investors and hedge funds have recently modified their holdings of PETS. Pinebridge Investments L.P. lifted its position in shares of PetMed Express by 1.0% during the 2nd quarter. Pinebridge Investments L.P. now owns 2,704 shares of the company’s stock worth $110,000 after buying an additional 27 shares during the period. Acrospire Investment Management LLC bought a new stake in PetMed Express in the second quarter valued at $110,000. Fred Alger Management Inc. bought a new stake in PetMed Express in the second quarter valued at $162,000. State of Alaska Department of Revenue grew its position in PetMed Express by 76.7% in the second quarter. State of Alaska Department of Revenue now owns 4,028 shares of the company’s stock valued at $163,000 after acquiring an additional 1,748 shares during the period. Finally, Bayesian Capital Management LP bought a new stake in PetMed Express in the second quarter valued at $203,000. 78.91% of the stock is owned by institutional investors and hedge funds.

About PetMed Express

PetMed Express, Inc (PetMed Express), doing business as 1800PetMeds, is a pet pharmacy. The Company markets prescription and non-prescription pet medications, and other health products for dogs and cats, direct to the consumer. It offers a selection of products for dogs and cats. Its product line contains approximately 3,000 stock keeping units (SKUS) of pet medications, health products and supplies.

Analyst Recommendations for PetMed Express (NASDAQ:PETS)

Receive News & Ratings for PetMed Express Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PetMed Express Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.